Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolioMarket Watch • 04/11/24
Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to WatchInvestopedia • 04/11/24
Vertex will buy Alpine Immune Sciences for $4.9B in another big Seattle biotech dealGeekWire • 04/11/24
Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion DealInvestors Business Daily • 04/10/24
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?Market Watch • 04/10/24
This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?The Motley Fool • 04/09/24
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.The Motley Fool • 04/09/24
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to KnowZacks Investment Research • 04/01/24
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney DiseaseBusiness Wire • 04/01/24